NCT04632225View on ClinicalTrials.gov

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

July 15, 2024

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

Engensis

Lyophilized biologic to be reconstituted containing Engensis

OTHER

Placebo

Injectable liquid

Trial Locations (5)

21205

Johns Hopkins University Department of Neurology, Baltimore

60611

Northwestern University, Chicago

78759

Austin Neuromuscular Center, Austin

85013

St. Joseph's Hospital and Medical Center, Barrows Neurological Institute, Phoenix

04763

Hanyang University Medical Center, Seoul

All Listed Sponsors
lead

Helixmith Co., Ltd.

INDUSTRY

NCT04632225 - Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter